HealthPharmaceuticals
CVS Adds Zepbound and Foundayo to Drug Plans
CVS Health is reinstating coverage for Eli Lilly's Zepbound and adding coverage for the anti-obesity pill Foundayo, expanding weight-loss tr...
12 days ago
HealthPharmaceuticals
J&J Wins Approval for First-of-its-Kind Psoriasis Pill Icotyde
3 months agoUS
Johnson & Johnson's Icotyde (icotrokinra) has secured FDA approval, marking a significant advancement in psoriasis treatment. This first-of-its-kind oral pill offers a new systemic treatment option for adults and adolescents with moderate-to-severe plaque psoriasis.
Key Insights
•
First Oral Targeted Therapy:: Icotyde is the first oral peptide designed to block the interleukin-23 (IL-23) receptor, a key driver of the inflammatory response in plaque psoriasis. Why this matters: Unlike injectable biologics, Icotyde provides a convenient once-daily oral administration.
•
Clinical Trial Success:: The approval is based on the Iconic Phase III program, involving approximately 2,500 patients across four Phase III studies. Why this matters: Approximately 70% of patients achieved clear or almost clear skin at week 16, and 55% achieved a PASI 90 response, demonstrating significant efficacy.
•
Broader Applications:: Johnson & Johnson is exploring Icotyde for additional immune-mediated indications, including psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Why this matters: This could position Icotyde as a platform therapy with broad potential beyond dermatology.
In-Depth Analysis
Background
Icotyde (icotrokinra) is an oral pill that blocks the IL-23 receptor, offering a novel approach to treating moderate-to-severe plaque psoriasis. The drug was jointly discovered by Protagonist Therapeutics and Johnson & Johnson, with J&J holding exclusive worldwide rights to develop and commercialize it.
Clinical Efficacy
The FDA approval was based on the Iconic clinical development program. Key findings from the Phase III studies include:
•
Approximately 70% of patients achieved clear or almost clear skin at week 16.
•
55% achieved a PASI 90 response (a 90% reduction in disease severity).
•
Adverse reaction rates were within 1.1% of placebo through week 16, with no new safety signals identified through week 52.
The Significance
The approval of Icotyde provides a new systemic treatment option for psoriasis patients, especially those who have not responded to topical treatments. It aligns with the International Psoriasis Council's guidance to transition to systemic therapy after two cycles of topical treatments.
Leah Howard, president and CEO of the National Psoriasis Foundation, noted that the approval of a novel systemic therapy changes the treatment conversation for the psoriasis community.
FAQs
What is Icotyde?
Icotyde is the first targeted oral peptide designed to block the interleukin-23 (IL-23) receptor, a key driver of the inflammatory response in plaque psoriasis. It is taken once daily by mouth.
What conditions is Icotyde approved to treat?
Icotyde is approved for adults and pediatric patients aged 12 and older who weigh at least 40 kg with moderate-to-severe plaque psoriasis and are candidates for systemic therapy or phototherapy.
What were the results of the clinical trials for Icotyde?
In superiority studies, approximately 70% of patients achieved clear or almost clear skin at week 16, and 55% achieved a PASI 90 response. Adverse reaction rates were within 1.1% of placebo through week 16, with no new safety signals identified through week 52.
Key Takeaways
•
Icotyde is a novel oral treatment for moderate-to-severe plaque psoriasis, offering an alternative to injectable biologics.
•
Clinical trials demonstrated significant efficacy and a favorable safety profile.
•
Johnson & Johnson is exploring Icotyde for additional immune-mediated diseases, potentially expanding its therapeutic applications.
Discussion
Do you think oral treatments like Icotyde will become the standard for psoriasis care? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
Related Articles
HealthPharmaceuticals
Novo Nordisk Expands Semaglutide Studies for Alcohol Use Disorder and Obesity
Novo Nordisk is broadening its research into semaglutide, originally developed for diabetes and obesity, to explore its potential in treatin...
about 1 month ago
HealthPharmaceuticals
NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment
After more than four decades, a new prescription medicine has emerged to combat motion sickness. Vanda Pharmaceuticals has announced the U.S...
about 1 month ago
HealthPharmaceuticals
TrumpRx Expands with AbbVie and Genentech, Raising Pricing Questions
Two major pharmaceutical companies, AbbVie and Genentech, are set to launch their medications on the TrumpRx platform, offering discounted p...
2 months ago
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer